Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012

Biomedica

Volumn 34, Issue 1, 2014, Pages 48-59

  Romero, Martín ^a   Chávez, Diana ^a   De Los Ríos, Magalí ^b   Álvis Guzmán, Nelson ^c  

^a Laboratorio de Salud Pública   (Colombia)

^b External Advisory Consultant in Hematology   (Colombia)

^c UNIVERSIDAD DE CARTAGENA   (Colombia)

Author keywords

BCR ABL positive; Chronic; Costs and cost analysis; Drug evaluation; Leukemia; Myelogenous; Protein tyrosine kinases

Indexed keywords

4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; BENZAMIDE DERIVATIVE; DASATINIB; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; COLOMBIA; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

BENZAMIDES; COLOMBIA; COST-BENEFIT ANALYSIS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES;

EID: 84901313677     PISSN: 01204157     EISSN: None     Source Type: Journal    
DOI: 10.7705/biomedica.v34i1.1446     Document Type: Article

References (39)

1. Espinosa Martínez E, Espinosa Estrada EE, Pavón Morán V, Hernández Padrón C, Ávila CabreraI O, Ramón Rodríguez L, et al. Tratamiento de la leucemia mieloide crónica con mesilato de imatinib en pacientes resistentes o intolerantes al interferón a recombinante: Resultados preliminares. Rev Cubana Hematol Inmunol Hemoter. 2010;26:12-26.
2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Chronic myelogenous leukemia, version 2.2011. Fort Washington, PA: National Comprehensive Cancer Network; 2011. p. 65.
3. American Cancer Society. Leukemia-chronic myeloid (myelogenous). Atlanta, GA: American Cancer Society; 2009. p. 40
4. Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:569-84. http://dx.doi.org/10.1016/j.hoc.2004.03.011
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300. http://dx.doi.org/10.3322/caac.20073
6. American Cancer Society. Cancer facts & figures. Atlanta, GA: American Cancer Society; 2010. p. 68.
7. Fausel C. Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007;64:S9-S15. http://dx.doi.org/10.2146/ajhp070482
8. Chávez González MA, Ayala Sánchez M, Mayani Viveros H. La leucemia mieloide crónica en el siglo XXI: biología y tratamiento. Rev Invest Clin. 2009;61:221-32.
9. Morales C, Torres V, Valencia J, Ribón G, Manrique R. Leucemia mieloide crónica: diagnóstico y tratamiento. Rev CES Med. 2010;24:97-108.
10. Goldman JM, Melo JV. Chronic myeloid leukemia - Advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-64. http://dx.doi.org/10.1056/NEJMra020777
11. Rodríguez M, Cardona AF, Grajales MA, Enciso L, Ruiz G, Yepes A, et al. Leucemia mieloide crónica en crisis blástica bases moleculares y diagnóstico. Rev Venez Oncol. 2007;19:287-96.
12. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-9. http://dx.doi.org/10.1056/NEJMoa0912614
13. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomized ENESTnd trial. Lancet Oncol. 2011;12:841-51. http://dx.doi.org/10.1016/S1470-2045(11)70201-7
14. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-70. http://dx.doi.org/10.1056/NEJMoa1002315
15. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2011;119:1123-9. http://dx.doi.org/10.1182/blood-2011-08-376087
16. Doggrell SA, Christensen AM. Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib$ Expert Opin Pharmacother. 2011;12:157-63. http://dx.doi.org/10.1517/14656566.2011.534780
17. Quintás-Cardama A, Cortes JE, Kantarjian HM. Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase. Cancer. 2011;117:5261-70. http://dx.doi.org/10.1002/cncr. 26196
18. O'Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ, et al. NCCN task force report: Tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw. 2011;9(Suppl.2):S1-25.
19. Baccarani M, Dreyling M, ESMO Guidelines Working Group. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl.4):105-7. http://dx.doi.org/10. 1093/annonc/mdp143
20. Combariza JF, Rodríguez ML, García JS, Acevedo M, Cardona AF, GálvezK, et al. Consenso sobre diagnóstico y tratamiento de leucemia mieloide crónica en Colombia. Rev Colomb Cancerol. 2008;12:126-42.
21. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Chronic myelogenous leukemia, version 2.2012. Fort Washington, PA: National Comprehensive Cancer Network; 2012. p. 75.
22. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683-91. http://dx.doi.org/10.1016/S0895-4356(97) 00049-8
23. Hughes TP.Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758-65.http://dx.doi.org/10.1182/blood-2010-03-273979
24. Ministerio de la Protección Social. Resolución 2569 de 2012. Bogotá: Ministerio de la Protección Social; 2012.
25. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2006;108:1809-20. http://dx.doi.org/10.1182/blood-2006-02-005686
26. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European Leukemia Net. J Clin Oncol. 2009;27:6041-51. http://dx.doi.org/10.1200/JCO.2009.25.0779
27. Departamento Administrativo Nacional de Estadística. Defunciones por grupos de edad y sexo, según departamento, municipio de residencia y grupos de causas de defunción (lista de causas agrupadas 6/67 CIE-10 de OPS). Bogotá: Departamento Administrativo Nacional de Estadística, DANE; 2008.
28. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J. 1996;313:275-283. http://dx.doi.org/10.1136/bmj. 313. 7052.275
29. Ministerio de Salud. Resolución 8430 de 1993. Bogotá: Ministerio de Salud; 1993.
30. Giles FJ, Rosti G, Beris P, Clark RE, le Coutre P, Mahon FX, et al. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study. Expert Rev Hematol. 2010;3:665-73. http://dx.doi.org/10.1586/ehm.10.61
31. Jabbour EC, Kantarjian JH. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Core Evid. 2010;4:207-13.
32. Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: Dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010;3:47. http://dx.doi.org/10.1186/1756-8722-3-47
33. Kim TD, Coutre Pl. The expanding role of nilotinib in chronic myeloid leukemia. Expert Opin Drug Saf. 2011;10:97-107. http://dx.doi.org/10.1517/14740338.2011.532486
34. Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin. 2011;27:1263-71. http://dx.doi.org/10.1185/03007995.2011.576238
35. Hoyle M, Pavey T, Ciani O, Jones-Hughes T, Osipenko L, Venkatachalamet M, et al. Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: Systematic reviews and economic analyses. National Institute for Health and Clinical Excellence (NICE): Peninsula Technology Assessment Group (PenTAG). Exeter: University of Exeter; 2011.
36. National Institute for Health and Clinical Excellence. Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib: Appraisal consultation document. London, UK: National Institute for Health and Clinical Excellence NICE; January 11, 2012. Fecha de consulta: 29 de marzo de 2012. Disponible en: http://guidance.nice.org.uk/TA/Wave24/15/Consultation/DraftGuidance.
37. Valencia JE, Orozco JJ. Adaptación a Colombia y Venezuela del modelo económico dasatinib primera línea del York Health Economics Consortium para el tratamiento de la leucemia mieloide crónica. Medwave. 2012;12:e5348. http://dx.doi.org/10.5867/medwave.2012.04.5348
38. Orozco-Giraldo JJ, Valencia JE, Aiello E, Caputo M. Evaluación económica del dasatinib en el tratamiento de la leucemia mieloide crónica en pacientes resistentes al imatinib en Chile. Medwave. 2011;11:e5012. http://dx.doi.org/10.5867/medwave.2011.04.5012
39. Scottish Intercollegiate Guidelines Network. SIGN 50 A guideline developer's handbook. Edinburg; Scotland: Scottish Intercollegiate Guidelines Network SIGN; 2008. p. 112.